Since ACC shows high levels of vascular endothelial growth factor (VEGF) (1, 11), some studies have focused on assessing the activity of sorafenib both in preclinical tumor models and in patients with adrenocortical cancer. Here, VEGFA is linked to adrenal cortex carcinoma.